JP2017526728A - 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト - Google Patents

炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト Download PDF

Info

Publication number
JP2017526728A
JP2017526728A JP2017514446A JP2017514446A JP2017526728A JP 2017526728 A JP2017526728 A JP 2017526728A JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017526728 A JP2017526728 A JP 2017526728A
Authority
JP
Japan
Prior art keywords
montelukast
levocetirizine
virus
combination
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017514446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526728A5 (cg-RX-API-DMAC7.html
Inventor
ブルース・チャンドラー・メイ
Original Assignee
インフラマトリー・レスポンス・リサーチ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インフラマトリー・レスポンス・リサーチ・インコーポレイテッド filed Critical インフラマトリー・レスポンス・リサーチ・インコーポレイテッド
Publication of JP2017526728A publication Critical patent/JP2017526728A/ja
Publication of JP2017526728A5 publication Critical patent/JP2017526728A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017514446A 2014-09-15 2015-09-11 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト Pending JP2017526728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050668P 2014-09-15 2014-09-15
US62/050,668 2014-09-15
PCT/US2015/049767 WO2016044095A1 (en) 2014-09-15 2015-09-11 Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020070422A Division JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Publications (2)

Publication Number Publication Date
JP2017526728A true JP2017526728A (ja) 2017-09-14
JP2017526728A5 JP2017526728A5 (cg-RX-API-DMAC7.html) 2018-10-11

Family

ID=55533713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514446A Pending JP2017526728A (ja) 2014-09-15 2015-09-11 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
JP2020070422A Pending JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020070422A Pending JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Country Status (4)

Country Link
US (4) US9925183B2 (cg-RX-API-DMAC7.html)
EP (1) EP3193875B1 (cg-RX-API-DMAC7.html)
JP (2) JP2017526728A (cg-RX-API-DMAC7.html)
WO (1) WO2016044095A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209035A1 (ko) * 2018-04-27 2019-10-31 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20190125943A (ko) * 2018-04-27 2019-11-07 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
JP2022500437A (ja) * 2018-09-14 2022-01-04 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159821A1 (en) 2010-06-16 2011-12-22 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
CN105517631A (zh) 2013-03-13 2016-04-20 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
JP2021536467A (ja) * 2018-09-06 2021-12-27 インノファーマスクリーン インコーポレイテッド 喘息またはパーキンソン病の処置のための方法および組成物
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20240000773A1 (en) * 2020-05-19 2024-01-04 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
JP2013528654A (ja) * 2010-06-16 2013-07-11 ブルース・チャンドラー・メイ インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
WO2013148366A1 (en) * 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
EP0612256B1 (en) 1991-11-14 1998-07-22 Alliance Pharmaceutical Corporation Apparatus for partial liquid ventilation using fluorocarbons
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
EP0994717A4 (en) 1997-01-24 2000-07-26 Autoimmune Inc TREATING AUTOIMMUNE DISEASES BY TOLERANCE INCREASED BY COMBINING WITH METHOTREXATE
PL193131B1 (pl) 1997-12-23 2007-01-31 Schering Corp Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
AU2470299A (en) 1998-01-27 1999-08-09 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US7186555B1 (en) 1999-04-13 2007-03-06 The Feinstein Institute For Medical Research Prevention of brain damage in stroke
US20020006961A1 (en) 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
JP2004505046A (ja) 2000-07-28 2004-02-19 イムファルム・アンパルトセルスカブ 感冒、アレルギー性鼻炎および気道に関連した感染症の症状の処置方法
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
ATE432068T1 (de) 2001-06-28 2009-06-15 Ucb Farchim Sa Cetirizin und pseudoephedrin enthaltende tablette
US20050176687A1 (en) 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
AU2003264859A1 (en) 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006010283A1 (en) 2004-07-28 2006-02-02 Universität Zürich Prevention and treatment of thrombus formation
AU2005294666A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056510A2 (en) 2005-11-09 2007-05-18 The Children's Hospital Of Philadelphia Chloride transport upregulation for the treatment of traumatic brain injury
ES2389231T3 (es) 2005-12-21 2012-10-24 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos, glucocorticoides y agonistas de beta2 para el tratamiento de enfermedades inflamatorias
US8207292B2 (en) 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
EP2129683A4 (en) 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
KR20100059836A (ko) 2007-08-15 2010-06-04 케마지스 리미티드 고순도 레보세티리진 및 이의 염을 제조하기 위한 신규한 방법
CA2701723A1 (en) 2007-10-25 2009-04-30 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
WO2009055614A1 (en) 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
HRP20140686T1 (hr) 2009-03-02 2014-09-26 Generics Poboljšani postupak
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
RU2012136624A (ru) 2010-01-28 2014-03-10 Мерк Шарп Энд Домэ Корп. Фармацевтические композиции для лечения боли и других показаний
US20120002637A1 (en) 2010-06-18 2012-01-05 Interdigital Patent Holdings, Inc. Method and apparatus for supporting home node-b mobility
EP2598143A1 (en) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmaceutical compositions for treatment of respiratory and inflammatory diseases
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
US20130030009A1 (en) 2010-12-30 2013-01-31 Ziv Harish Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen
EP2658538A2 (en) 2010-12-30 2013-11-06 M.D. Ziv Harish Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables
CN103561722A (zh) 2011-04-13 2014-02-05 利发利希奥公司 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
JP5860960B2 (ja) 2011-07-26 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キノリン類及び医薬としてのそれらの使用
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
RU2705097C2 (ru) 2013-03-13 2019-11-05 Ирр, Инк. Применение левоцетиризина и монтелукаста при лечении анафилаксии
EP2968309A4 (en) 2013-03-13 2016-08-31 Inflammatory Response Res Inc USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY
CN105228700A (zh) 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
CN105517631A (zh) 2013-03-13 2016-04-20 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
JP2019517581A (ja) 2016-06-03 2019-06-24 アイ・アール・アール・インコーポレイテッド 放射線媒介性状態の処置におけるレボセチリジン及びモンテルカスト
US20240000773A1 (en) 2020-05-19 2024-01-04 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
JP2013528654A (ja) * 2010-06-16 2013-07-11 ブルース・チャンドラー・メイ インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
WO2013148366A1 (en) * 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPHARMCOLOGY, vol. 79, JPN6019019029, April 2014 (2014-04-01), pages 707 - 714, ISSN: 0004041719 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209035A1 (ko) * 2018-04-27 2019-10-31 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20190125943A (ko) * 2018-04-27 2019-11-07 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20200116068A (ko) * 2018-04-27 2020-10-08 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20200116069A (ko) * 2018-04-27 2020-10-08 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269664B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269663B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269665B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
JP2022500437A (ja) * 2018-09-14 2022-01-04 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
JP7759693B2 (ja) 2018-09-14 2025-10-24 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Also Published As

Publication number Publication date
US11590125B2 (en) 2023-02-28
US20180169091A1 (en) 2018-06-21
US20190201393A1 (en) 2019-07-04
JP2020109128A (ja) 2020-07-16
US20170173001A1 (en) 2017-06-22
WO2016044095A1 (en) 2016-03-24
EP3193875B1 (en) 2022-02-16
US9925183B2 (en) 2018-03-27
US20210177835A1 (en) 2021-06-17
EP3193875A1 (en) 2017-07-26
US10792281B2 (en) 2020-10-06
US10195193B2 (en) 2019-02-05
EP3193875A4 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
US11590125B2 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
Bhattacharya et al. Role of neuro-immunological factors in the pathophysiology of mood disorders
AU2025210905A1 (en) Method of treatment with tradipitant
BR112021002945A2 (pt) dosagem noturna crônica de lasmiditan para prevenção de enxaqueca
Andrews et al. Sleep–wake disturbance related to ocular disease: a systematic review of phase-shifting pharmaceutical therapies
WO2023287556A1 (en) Methods of treating alzheimer's disease
Saha et al. Individualized homoeopathy versus placebo in essential hypertension: A double-blind randomized controlled trial
US20180318338A1 (en) Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
HK1240843A1 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
HK1240843B (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
Mythri et al. Coronavirus disease-19 vaccination and chemosensory dysfunction
Anderer High drug costs influence nonadherence to medications among older adults
Peterson An experimental evaluation of central pain processing following COVID-19 infection
US20230190734A1 (en) Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof
KR20250153297A (ko) 샤르코-마리-투스병의 치료를 위한 조성물 및 방법
Aliev et al. Infectious Burden and Alzheimer Disease: Is There a Link?
Saad D-β-Hydroxybutyrate and lactate mediate the positive effects of exercise on chronic stress by changing the histone modification profile in the hippocampus
Cabaret False resistance to antiparasitic drugs: causes from shelf availability to patient compliance
Anderer New Tick-Borne Virus Identified in China
Anderer CDC Reports Human Case of Bird Flu Not Linked to Animals
Anderer Caseload Strain Contributed to 1 in 5 COVID-19 Deaths at US Hospitals
Anderer FDA Issues Rules Restricting the Sale of Tobacco to Those 21 Years or Older
Shah et al. A Randomized, Placebo-controlled Homeopathic Drug-proving of SARS CoV-2 nosode (BiosimCovex) in healthy volunteers: Homeopathic Pathogenetic Trial of SARS CoV-2 nosode
Anderer Study: Fentanyl’s Arrival, Not Oregon’s Drug Law, Likely Explains State’s Overdose Surge
JP2025532301A (ja) 重症筋無力症を処置するための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191209